Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.

In individuals with multiple sclerosis (MS) spasticity, associated symptoms such as spasms, pain, mobility restrictions and sleep disturbances can interfere with the ability to perform activities of daily living and reduce quality of life (QoL). Recent cross-sectional studies from Europe have confirmed that advancing severity of MS spasticity correlates directly with worsening QoL. The treatment effect of Sativex(®) (GW Pharmaceuticals PLC, Porton Down, UK; Laboratorios Almirall, SA, Barcelona, Spain) on QoL has been evaluated in randomized controlled trials, observational studies conducted under everyday clinical practice conditions and a survey in long-term users. Symptomatic relief of MS spasticity in responders to Sativex was associated with quantifiable improvements in QoL and activities of daily living that were maintained over time. Benefits were perceived by both patients and caregivers.

[1]  U. Zettl,et al.  Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice , 2014, European Neurology.

[2]  U. Zettl,et al.  Spasticity in patients with multiple sclerosis – clinical characteristics, treatment and quality of life , 2014, Acta neurologica Scandinavica.

[3]  U. Zettl,et al.  Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity , 2014, European Neurology.

[4]  S. Borg,et al.  Costs and quality of life in multiple sclerosis patients with spasticity , 2014, Acta neurologica Scandinavica.

[5]  J. Farrar.  Measuring symptoms and wellness in the multiple sclerosis patient: issues in measurement , 2013, Expert review of neurotherapeutics.

[6]  G. Cutter,et al.  Natural history of multiple sclerosis symptoms. , 2013, International journal of MS care.

[7]  C. Vila,et al.  Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study , 2013, The International journal of neuroscience.

[8]  C. Oreja-Guevara,et al.  Spasticity in multiple sclerosis: results of a patient survey , 2013, The International journal of neuroscience.

[9]  V. Demarin,et al.  Quality of life in patients with multiple sclerosis. , 2013, Acta clinica Croatica.

[10]  W. Notcutt.  A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine , 2012, Primary Health Care Research & Development.

[11]  P. Vermersch,et al.  [Epidemiology and clinical assessment of spasticity in multiple sclerosis]. , 2012, Revue neurologique.

[12]  C. Pozzilli,et al.  A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols * (Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis , 2011, European journal of neurology.

[13]  C. Vila,et al.  Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study , 2011, Expert review of pharmacoeconomics & outcomes research.

[14]  C. Collin,et al.  A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis , 2010, Neurological research.

[15]  J. Farrar,et al.  Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. , 2008, Clinical therapeutics.

[16]  A J Thompson,et al.  Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). , 2006, Brain : a journal of neurology.

[17]  J. Holmes,et al.  What drives quality of life in multiple sclerosis? , 2004, QJM : monthly journal of the Association of Physicians.

[18]  T. Vollmer,et al.  Prevalence and treatment of spasticity reported by multiple sclerosis patients , 2004, Multiple sclerosis.

[19]  L. Kalra,et al.  Who should measure quality of life? , 2001, BMJ : British Medical Journal.

[20]  D. Felce,et al.  Quality of life: its definition and measurement. , 1995, Research in developmental disabilities.